KURA - Kura Oncology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
16.87
+0.41 (+2.49%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close16.46
Open16.51
Bid16.90 x 1200
Ask25.25 x 1300
Day's Range16.14 - 16.87
52 Week Range10.20 - 24.02
Volume168,717
Avg. Volume289,469
Market Cap641.293M
Beta (3Y Monthly)3.46
PE Ratio (TTM)N/A
EPS (TTM)-1.67
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.29
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    Kura Oncology to Present at J.P. Morgan Healthcare Conference

    SAN DIEGO, Jan. 03, 2019 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today.

  • Kura Oncology, Inc. (KURA): Are Hedge Funds Right About This Stock?
    Insider Monkeylast month

    Kura Oncology, Inc. (KURA): Are Hedge Funds Right About This Stock?

    The government requires hedge funds and wealthy investors with over a certain portfolio size to file a report that shows their positions at the end of every quarter. Even though it isn’t the intention, these filings level the playing field for ordinary investors. The latest round of 13F filings disclosed the funds’ positions on September […]

  • Thomson Reuters StreetEventslast month

    Edited Transcript of KURA earnings conference call or presentation 5-Nov-18 9:30pm GMT

    Q3 2018 Kura Oncology Inc Earnings Call

  • GlobeNewswirelast month

    Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma

    – Two CRs, four PRs (46% ORR) observed in advanced AITL patients in Phase 2 trial of tipifarnib in PTCL – – AITL and other PTCL patients with high CXCL12 expression experienced.

  • GlobeNewswire2 months ago

    Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a new patent protecting the Company's lead drug candidate, tipifarnib, a potent and selective farnesyl transferase that is currently being studied in multiple solid tumor and hematologic indications, including a registration-directed trial in HRAS mutant head and neck squamous cell carcinoma (HNSCC) and a Phase 2 trial in peripheral T-cell lymphoma (PTCL). U.S. Patent No. 10,137,121, “Methods of Treating Cancer with Farnesyltransferase Inhibitors,” includes multiple claims directed to the use of tipifarnib as a method of treating patients with angioimmunoblastic T-cell lymphoma (AITL), an aggressive form of T-cell lymphoma.

  • GlobeNewswire2 months ago

    Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors

    Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the appointment of commercial veteran Mary Szela to its board of directors. Throughout her 30-year career in the biopharmaceutical industry, Ms. Szela has served on a number of high-profile boards, developed global brands and led the world’s largest selling pharmaceutical product, Humira®, through the launch of five indications. “Mary’s strategic vision and track record in the commercial arena make her a valuable addition to our board,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology.

  • GlobeNewswire2 months ago

    Kura Oncology to Participate in Two Upcoming Investor Conferences

    SAN DIEGO, Nov. 06, 2018 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today.

  • Associated Press2 months ago

    Kura Oncology: 3Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 40 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas

    SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the initiation of its global, multi-center, registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC). “We are excited to announce that our first registration-directed trial is now underway,” said Antonio Gualberto, M.D., Ph.D., Head of Development and Chief Medical Officer of Kura Oncology. “Prior to our experience, tipifarnib was studied in more than 5,000 patients and although it demonstrated compelling anti-cancer activity in some cases, no molecular target was identified that could explain such activity.

  • GlobeNewswire2 months ago

    Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting

    SAN DIEGO, Nov. 01, 2018 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today.

  • GlobeNewswire3 months ago

    Kura Oncology to Report Third Quarter 2018 Financial Results

    SAN DIEGO, Oct. 29, 2018 -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today.

  • 3 Beaten-Down Biotech Stocks: Can They Bounce Back?
    Motley Fool3 months ago

    3 Beaten-Down Biotech Stocks: Can They Bounce Back?

    See if these oncology-driven drugmakers have what it takes to recover from recent setbacks.

  • GlobeNewswire3 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Dropbox, Kura Oncology, DHT, Wayfair, US Foods Holding, and InflaRx N.V — New Research Emphasizes Economic Growth

    NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Here's Why Kura Oncology Fell Today
    Motley Fool3 months ago

    Here's Why Kura Oncology Fell Today

    The biotech's drug works -- just not on as many people as investors would have hoped for.

  • Precision Medicine Oncology Pipeline Is Key for Kura Oncology
    Market Realist4 months ago

    Precision Medicine Oncology Pipeline Is Key for Kura Oncology

    Kura Oncology (KURA) is a clinical-stage biopharmaceutical company focused on advancing its research pipeline of precision medicine targeting genetically-defined hematologic malignancies and solid tumors. Kura Oncology has reported returns of 0.59%, -12.31%, -7.57%, and 37.90% in the last week, the last month, the last quarter, and the last year, respectively. The 12-month consensus analyst recommendation for Kura Oncology on September 23 is a “strong buy.” The 12-month consensus target price for Kura Oncology is $30.33, which is 77.37% higher than the company’s closing price on September 21.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of KURA earnings conference call or presentation 6-Aug-18 8:30pm GMT

    Q2 2018 Kura Oncology Inc Earnings Call

  • Associated Press5 months ago

    Kura Oncology: 2Q Earnings Snapshot

    On a per-share basis, the San Diego-based company said it had a loss of 45 cents. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • ACCESSWIRE5 months ago

    Kura Oncology, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Kura Oncology, Inc. (NASDAQ: KURA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern Time. ...